Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
The Lancet. Respiratory Medicine
|
November 25, 2015
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
François Spertini, Régine Audran, Reza Chakour, et al.
Frontiers in Microbiology
|
July 7, 2020
Respiratory Immunization With a Whole Cell Inactivated Vaccine Induces Functional Mucosal Immunoglobulins Against Tuberculosis in Mice and Non-human Primates
Nacho Aguilo, Santiago Uranga, Elena Mata, et al.
NPJ Vaccines
|
November 20, 2024
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Marco Polo Peralta-Álvarez, Keya Downward, Andrew White, et al.
Frontiers in Immunology
|
May 27, 2024
Low-dose <i>M.tb</i> infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
Marco Polo Peralta Alvarez, Holly Jones, Hugo Redondo Azema, et al.
Science Immunology
|
September 24, 2021
Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis
Elena Mata, Raquel Tarancon, Claudia Guerrero, et al.
Cell Reports. Medicine
|
February 1, 2021
Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection
Karin Dijkman, Nacho Aguilo, Charelle Boot, et al.
The Lancet. Respiratory Medicine
|
August 17, 2019
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial
Michele Tameris, Helen Mearns, Adam Penn-Nicholson, et al.
Ebiomedicine
|
March 18, 2025
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting
Michele Tameris, Virginie Rozot, Claire Imbratta, et al.
The Lancet. Global Health
|
April 18, 2025
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial
Angelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, et al.
Cell Reports. Medicine
|
February 1, 2021
Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination
Michel P M Vierboom, Karin Dijkman, Claudia C Sombroek, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
The Lancet. Respiratory Medicine
|
November 25, 2015
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
François Spertini, Régine Audran, Reza Chakour, et al.
Frontiers in Microbiology
|
July 7, 2020
Respiratory Immunization With a Whole Cell Inactivated Vaccine Induces Functional Mucosal Immunoglobulins Against Tuberculosis in Mice and Non-human Primates
Nacho Aguilo, Santiago Uranga, Elena Mata, et al.
NPJ Vaccines
|
November 20, 2024
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
Marco Polo Peralta-Álvarez, Keya Downward, Andrew White, et al.
Frontiers in Immunology
|
May 27, 2024
Low-dose <i>M.tb</i> infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
Marco Polo Peralta Alvarez, Holly Jones, Hugo Redondo Azema, et al.
Science Immunology
|
September 24, 2021
Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis
Elena Mata, Raquel Tarancon, Claudia Guerrero, et al.
Cell Reports. Medicine
|
February 1, 2021
Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection
Karin Dijkman, Nacho Aguilo, Charelle Boot, et al.
The Lancet. Respiratory Medicine
|
August 17, 2019
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial
Michele Tameris, Helen Mearns, Adam Penn-Nicholson, et al.
Ebiomedicine
|
March 18, 2025
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting
Michele Tameris, Virginie Rozot, Claire Imbratta, et al.
The Lancet. Global Health
|
April 18, 2025
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial
Angelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, et al.
Cell Reports. Medicine
|
February 1, 2021
Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination
Michel P M Vierboom, Karin Dijkman, Claudia C Sombroek, et al.
Page
of 4